<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02061085</url>
  </required_header>
  <id_info>
    <org_study_id>OBU-SW-H-02</org_study_id>
    <secondary_id>2012-004463-41</secondary_id>
    <nct_id>NCT02061085</nct_id>
  </id_info>
  <brief_title>Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment</brief_title>
  <acronym>MERIBEL</acronym>
  <official_title>A Phase IIa Prospective, Multicenter, Open and Not Controlled of the Efficacy and Tolerability on the First Line Treatment With Eribulin as a Unic Agent on Patients With HER2 Negative Metastatic Breast Cancer Previously Treated With Taxanes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedSIR</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedSIR</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentre, prospective, non-controlled phase II clinical trial to evaluate the efficacy and&#xD;
      tolerability of first line single agent Eribulin in patients with HER2-negative metastatic&#xD;
      breast carcinoma previously exposed to taxanes for early stage.&#xD;
&#xD;
      The primary objective of the study is to determine the median time to progression achieved&#xD;
      with Eribulin. Other secondary objectives will be; overall response rate, clinical benefit&#xD;
      rate, time to treatment progression, duration of response and toxicity profile.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median time to disease progression and treatment benefit variable</measure>
    <time_frame>Up to two years from the last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Up to one year from the first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate</measure>
    <time_frame>Up to one year from the first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until progression after the treatment</measure>
    <time_frame>Up to two years from the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median duration of response</measure>
    <time_frame>Up to one year from the first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of eribulin in terms of adverse reactions</measure>
    <time_frame>Up to two years form the last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Utility functional hepatic levels as criteria for dose modifications instead of the Child-Pugh classification system for the assessment of liver involvement</measure>
    <time_frame>Up to one year form the last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Breast Neoplasm</condition>
  <condition>Metastasis</condition>
  <arm_group>
    <arm_group_label>monotherapy treatment with Eribulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eribulin Dosage: 1.4 mg/m2 Route of administration: IV bolus Schedule of cycle: D1 and D8 every 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eribulina</intervention_name>
    <arm_group_label>monotherapy treatment with Eribulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed metastatic breast cancer HER2 negative, stage IIIb/IV&#xD;
&#xD;
          -  Previous history of early disease (stage I-IIIb), surgically resected and treated with&#xD;
             standard chemotherapy for at least 12 weeks at which included a taxane or ixabepilone&#xD;
&#xD;
          -  Patients must have progressed in the 36 months after treatment with taxanes or&#xD;
             ixabepilone.&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Given written informed consent&#xD;
&#xD;
          -  Index of Eastern Cooperative Oncology Group (ECOG) of 0 or 1&#xD;
&#xD;
          -  Patients must have recovered from toxicities related with previous treatment (CTC ≥ 1)&#xD;
&#xD;
          -  Measurable or evaluable disease (RECIST 1.1)&#xD;
&#xD;
          -  Adequate bone marrow function&#xD;
&#xD;
          -  Adequate hepatic function&#xD;
&#xD;
          -  Adequate renal function&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Breast cancer patients initially diagnosed with local disease advanced or metastatic&#xD;
             disease.&#xD;
&#xD;
          -  Patients who have previously received cytotoxic therapy Hormone therapy permitted if&#xD;
             the patients have interrupted it at least two weeks before the start of the study&#xD;
             treatment.&#xD;
&#xD;
          -  Major surgery or significant traumatic injury during the 4 weeks prior to study&#xD;
             treatment or patients who may require major surgery during the assay.&#xD;
&#xD;
          -  Brain metastases or leptomeningeal uncontrolled.&#xD;
&#xD;
          -  Serious medical condition and / or not properly controlled (unstable angina, lung&#xD;
             function severe impaired, uncontrolled diabetes, active serious infection,liver&#xD;
             disease, HIV seropositivity, active bleeding diathesis)&#xD;
&#xD;
          -  Other malignancies in the last three years, except: cervical carcinoma in situ, basal&#xD;
             cell carcinoma or squamous cell skin carcinoma,that have been properly treated&#xD;
&#xD;
          -  Patients who are pregnant or breastfeeding, or adults with reproductive capacity wich&#xD;
             are not using effective contraception.&#xD;
&#xD;
          -  Patients receiving chronic treatment with systemic corticosteroids or other&#xD;
             immunosuppressive drugs (except corticosteroids with a daily dose equivalent to&#xD;
             prednisone ≤ 20mg on a stable dose regimen one minimum of 4 weeks prior to study&#xD;
             entry. Topical and inhaled corticosteroids are allowed&#xD;
&#xD;
          -  Active alcoholism or drugs addiction documented.&#xD;
&#xD;
          -  Prior history of noncompliance with medical regimens&#xD;
&#xD;
          -  Patients who do not want or can not comply with the study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Llombart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Valencia</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Zaragoza</city>
        <state>Aragón</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salamanca</city>
        <state>Castilla Y León</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Badajoz</city>
        <state>Extremadura</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Coruña</city>
        <state>Galicia</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palma de Mallorca</city>
        <state>Illes Balears</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gran Canaria</city>
        <state>Islas Canarias</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>January 10, 2014</study_first_submitted>
  <study_first_submitted_qc>February 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2014</study_first_posted>
  <last_update_submitted>November 25, 2020</last_update_submitted>
  <last_update_submitted_qc>November 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Neoplasm Metastasis</keyword>
  <keyword>Receptor,HER-2</keyword>
  <keyword>Eribulin</keyword>
  <keyword>Furans, quetones</keyword>
  <keyword>Antimitotic agent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

